Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Gains from Investment Securities (2016 - 2025)

Bio-Techne (TECH) has 17 years of Gains from Investment Securities data on record, last reported at -$500000.0 in Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 162.5% year-over-year to -$500000.0; the TTM value through Dec 2025 reached $86.4 million, up 10699.75%, while the annual FY2025 figure was $9.5 million, 90.62% down from the prior year.
  • Gains from Investment Securities reached -$500000.0 in Q4 2025 per TECH's latest filing, down from $900000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $232.0 million in Q1 2023 and bottomed at -$50.8 million in Q1 2021.
  • Average Gains from Investment Securities over 5 years is $21.4 million, with a median of $9.5 million recorded in 2025.
  • Peak YoY movement for Gains from Investment Securities: crashed 6444.37% in 2021, then surged 7390.66% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at $25.0 million in 2021, then tumbled by 90.8% to $2.3 million in 2022, then skyrocketed by 838.48% to $21.6 million in 2023, then tumbled by 96.29% to $800000.0 in 2024, then plummeted by 162.5% to -$500000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$500000.0 in Q4 2025, $900000.0 in Q3 2025, and $9.5 million in Q2 2025.